REATA PHARMACEUTICALS, INC. Inactive Instrument
Reata Pharmaceuticals, Inc.
Equities
RETA
US75615P1030
Biotechnology & Medical Research
Presentation Operator MessageOperator (Operator)Hello and welcome to the Reata Pharmaceuticals...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing therapies. The Company concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The Company's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. It is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.
Calendar
2025-05-12
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.67% | 114B | |
| +11.13% | 104B | |
| -12.94% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.44% | 17.89B | |
| +7.82% | 14.28B | |
| +35.39% | 12.55B |
